Metformina Dinerfene Laboratórios Azevedos – Indústria Farmacêutica

Metformin Hydrochloride, the active ingredient in Metformina Dinerfene, is a biguanide presented as an oral tablet for oral use. It is used to improve glycemic control in adults with type 2 diabetes mellitus and is indicated for patients who require adjunctive therapy when diet and exercise alone are insufficient.

GNH USA supplies Metformina Dinerfene as a licensed, GDP‑compliant international pharmaceutical product serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by insulin resistance and elevated blood glucose levels, and is used as part of a comprehensive therapeutic regimen that includes diet, exercise and other antidiabetic agents.

- Type 2 diabetes mellitus: improves blood glucose levels and reduces HbA1c when used as part of a comprehensive treatment plan.

Metformin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools, especially during initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycemia: usually when combined with other glucose‑lowering agents. - Anemia: due to reduced red blood cell production. - Electrolyte imbalance: especially with prolonged diarrhea.

Metformin should be used with careful clinical monitoring. - Renal function assessment: avoid or adjust dose in patients with impaired kidney function. - Hepatic function monitoring: use cautiously in liver disease. - Lactic acidosis risk: discontinue before radiologic contrast procedures. - Elderly patients: start at low dose and titrate slowly. - Heart failure: evaluate severity before initiation. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformin may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; withhold metformin before and after imaging. - Cimetidine: can raise metformin plasma concentrations. - Alcohol excess: potentiates lactic acidosis. - Rifampicin: may reduce metformin effectiveness.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Other antidiabetic agents: risk of additive hypoglycemia. - Thyroid hormones: may alter glucose metabolism.